Connect to other sites within the UBM Medica Network
Spit-Based Test Could Predict Oral Cancer Recurrence
A new study found that in patients treated for oropharyngeal cancer, the detection of HPV16 DNA via an oral rinse could be a sign of poor prognosis.
TKIs Have Kidney Effects in Long-Term CML Treatment
Treatment of CML with various tyrosine kinase inhibitors can induce changes in glomerular filtration rate over time and have other kidney-related effects.
Long-Term Survival Possible With MAPK Inhibition in BRAF-Mutant Melanoma
Results of a study suggest that durable survival is possible in melanoma patients treated with MAPK inhibitors, and is perhaps similar to the survival observed with ipilimumab.
NF1 Mutation Present in Many BRAF, NRAS Wildtype Melanomas
Whole-exome sequencing found that mutations of the NF1 gene are an important driver mutation in melanoma, and the third most frequently mutated gene.
Nomograms Help Predict Survival Outcomes in Osteosarcoma Patients
A retrospective study was used to develop nomograms predictive of both metastasis-free and overall survival for patients with nonmetastatic osteosarcoma.
Carbonyl Compounds in Breath Could Help Diagnose Lung Cancer
Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.
Carfilzomib Gets Expanded FDA Approval for Multiple Myeloma
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.